Comparative Pharmacology
Head-to-head clinical analysis: BESIVANCE versus FML S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BESIVANCE versus FML S.
BESIVANCE vs FML-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BESIVANCE is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and leading to bacterial cell death.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
One drop instilled into the affected eye(s) three times daily for 7 days.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
None Documented
None Documented
Terminal half-life of approximately 1.5-2 hours in adults; prolongation in renal impairment.
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Primarily excreted unchanged in urine (approximately 50-60%) and feces (approximately 20-30%); biliary excretion contributes to fecal elimination.
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination